ROLE of PLATELETS in the PATHOPHYSIOLOGY of SYSTEMIC LUPUS

Plain-language summary

This study investigates the role of platelets in the development of systemic lupus erythematosus and certain other immune-system diseases. Patients aged 18-70 with confirmed diagnoses such as lupus, systemic scleroderma, or rheumatoid arthritis can take part. It is a study without an assigned phase and is still enrolling participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

University Hospital, Strasbourg, France

Start date

1/9/2024

Estimated completion

1/9/2029

Countries

France

Related genes

Locations

• Strasbourg, France

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Patients between 18 and 70 years of age
* Patient affiliated to a health insurance scheme (beneficiary or beneficiary's beneficiary)
* Patient able to understand the aims and risks of research
* Patient having signed and dated an informed consent form
* Patient for whom the diagnosis of at least one of the following pathologies has been confirmed:
* Systemic lupus erythematosus meeting ACR/EULAR 20195 classification criteria.
* Systemic scleroderma meeting ACR/EULAR 20136 classification criteria.
* ANCA vasculitis according to EULAR/ACR 2022.7-9 classification criteria.
* Inflammatory myositis according to EULAR/ACR 201710 classification criteria.
* Gougerot-Sjögren syndrome according to EULAR/ACR 2016 classification criteria11.
* Rheumatoid arthritis according to ACR/EULAR 201012 classification criteria.

Exclusion Criteria:

* Patient in exclusion period (determined by a previous or current study)
* Inability to give patient informed consent (patient in emergency or immediate life-threatening situation)
* Patient under court protection
* Patient under guardianship or curatorship